SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology & Drugs
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: SusieQ1065 who wrote (108)7/10/2002 7:16:31 PM
From: SusieQ1065  Read Replies (1) of 232
 
16:36 ET IDPH IDEC Pharm issues guidance (30.15 -2.66)
Announced that it estimates Q2 preliminary EPS to be $0.20, vs the Multex consensus of $0.19. Co says this level of net income was achieved through the combination of U.S. net sales of Rituxan totaling $257.4 million for the qtr, which IDPH copromotes in the U.S. with DNA, and U.S. net sales of Zevalin totaling $3.3 mln, which IDPH markets alone in the U.S.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News